SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-23-057527
Filing Date
2023-11-01
Accepted
2023-11-01 16:40:06
Documents
2
Period of Report
2023-10-30

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1629
2 EX-24 vrdn-ex24.htm EX-24 9531
  Complete submission text file 0000950170-23-057527.txt   12888
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Issuer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8071 Services-Medical Laboratories

Mailing Address C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE, 2 CHURCH STREET HAMILTON D0 HM11
Business Address
Beetham Thomas W. (Reporting) CIK: 0001741382 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36483 | Film No.: 231368823